The DestinyLung01 study showed that the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) led to a confirmed objective response rate (ORR) of 61.9% in patients with relapsed/refractory HER2-mutant NSCLC (n = 42) [6]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.